Resultats de la cerca - Lode J. Swinnen

Refinar resultats
  1. 1
    Methylation Status of the Epstein-Barr Virus Major Latent Promoter C in Iatrogenic B Cell Lymphoproliferative Disease

    Methylation Status of the Epstein-Barr Virus Major Latent Promoter C in Iatrogenic B Cell Lymphoproliferative Disease per Qian Tao, Lode J. Swinnen, Jie Yang, Gopesh Srivastava, Keith D. Robertson, Richard F. Ambinder

    Publicat 1999
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  2. 2
    Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation1

    Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation1 per Wida S. Cherikh, H. Myron Kauffman, Maureen McBride, Jude Maghirang, Lode J. Swinnen, Douglas W. Hanto

    Publicat 2003
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  3. 3
    Challenges in the Treatment of Newly Diagnosed and Recurrent Primary Central Nervous System Lymphoma

    Challenges in the Treatment of Newly Diagnosed and Recurrent Primary Central Nervous System Lymphoma per Matthias Holdhoff, Maciej M. Mrugała, Christian Grommes, Thomas Kaley, Lode J. Swinnen, Carlos A. Perez-Heydrich, Lakshmi Nayak

    Publicat 2020
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  4. 4
    Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404)

    Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperati... per Kristen N. Ganjoo, Fangxin Hong, Sandra J. Horning, Randy D. Gascoyne, Yasodha Natkunam, Lode J. Swinnen, Thomas M. Habermann, Brad S. Kahl, Ranjana H. Advani

    Publicat 2013
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  5. 5
    Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study

    Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study per Sandra J. Horning, Malik E. Juweid, Heiko Schöder, Gregory A. Wiseman, Alex McMillan, Lode J. Swinnen, Ranjana H. Advani, Randy D. Gascoyne, Andrew Quon

    Publicat 2009
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  6. 6
    Response‐adapted therapy for aggressive non‐Hodgkin's lymphomas based on early [18F] FDG‐PET scanning: ECOG‐ACRIN Cancer Research Group study (E3404)

    Response‐adapted therapy for aggressive non‐Hodgkin's lymphomas based on early [18F] FDG‐PET scanning: ECOG‐ACRIN Cancer Research Group study (E3404) per Lode J. Swinnen, Hailun Li, Andrew Quon, Randy D. Gascoyne, Fangxin Hong, Erik A. Ranheim, Thomas M. Habermann, Brad S. Kahl, Sandra J. Horning, Ranjana H. Advani

    Publicat 2015
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  7. 7
    Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage

    Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage per Genevieve M. Crane, Helen Powell, Rumen Kostadinov, Patrick Tim Rocafort, Dena E. Rifkin, Peter C. Burger, Richard F. Ambinder, Lode J. Swinnen, Michael J. Borowitz, Amy S. Duffield

    Publicat 2015
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  8. 8
    Prospective Study of Sequential Reduction in Immunosuppression, Interferon Alpha-2B, and Chemotherapy for Posttransplantation Lymphoproliferative Disorder

    Prospective Study of Sequential Reduction in Immunosuppression, Interferon Alpha-2B, and Chemotherapy for Posttransplantation Lymphoproliferative Disorder per Lode J. Swinnen, Michael LeBlanc, Thomas M. Grogan, Leo I. Gordon, Patrick J. Stiff, Alan M. Miller, Yvette L. Kasamon, Thomas P. Miller, Richard I. Fisher

    Publicat 2008
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  9. 9
    Increased Incidence of Lymphoproliferative Disorder after Immunosuppression with the Monoclonal Antibody OKT3 in Cardiac-Transplant Recipients

    Increased Incidence of Lymphoproliferative Disorder after Immunosuppression with the Monoclonal Antibody OKT3 in Cardiac-Transplant Recipients per Lode J. Swinnen, Maria Rosa Costanzo‐Nordin, Susan G. Fisher, E. Jeanne O'Sullivan, Maryl R. Johnson, Alain Heroux, George J. Dizikes, R Pifarré, Richard I. Fisher

    Publicat 1990
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  10. 10
    EPSTEIN-BARR VIRUS-INDUCED POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERS

    EPSTEIN-BARR VIRUS-INDUCED POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERS per Carlos V. Payá, John J. Fung, Michael A. Nalesnik, Elliott Kieff, Michael Green, Gregory Gores, Thomas M. Habermann, Russell H. Wiesner, Lode J. Swinnen, E. Steve Woodle, Jonathan S. Bromberg

    Publicat 1999
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  11. 11
    Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide

    Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide per Laura Schoch, Kenneth R. Cooke, Nina D. Wagner‐Johnston, Ivana Gojo, Lode J. Swinnen, Philip Imus, Ephraim J. Fuchs, Mark J. Levis, Richard F. Ambinder, Richard J. Jones, Douglas E. Gladstone

    Publicat 2018
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  12. 12
    Phase II Study of Risk-Adapted Therapy of Newly Diagnosed, Aggressive Non-Hodgkin Lymphoma Based on Midtreatment FDG-PET Scanning

    Phase II Study of Risk-Adapted Therapy of Newly Diagnosed, Aggressive Non-Hodgkin Lymphoma Based on Midtreatment FDG-PET Scanning per Yvette L. Kasamon, Richard L. Wahl, Harvey A. Ziessman, Amanda L. Blackford, Steven N. Goodman, Caroline A. Fidyk, Kathryn Rogers, Javier Bolaños‐Meade, Michael J. Borowitz, Richard F. Ambinder, Richard J. Jones, Lode J. Swinnen

    Publicat 2009
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  13. 13
    Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma

    Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma per Yvette L. Kasamon, Heather A. Jacene, Christopher D. Gocke, Lode J. Swinnen, Douglas E. Gladstone, Brandy Perkins, Brian K. Link, Leslie Popplewell, Thomas M. Habermann, Joseph M. Herman, William Matsui, Richard J. Jones, Richard F. Ambinder

    Publicat 2012
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  14. 14
    Outcomes of Related Donor HLA-Identical or HLA-Haploidentical Allogeneic Blood or Marrow Transplantation for Peripheral T Cell Lymphoma

    Outcomes of Related Donor HLA-Identical or HLA-Haploidentical Allogeneic Blood or Marrow Transplantation for Peripheral T Cell Lymphoma per Jennifer A. Kanakry, Yvette L. Kasamon, Christopher D. Gocke, Hua-Ling Tsai, Janice Davis‐Sproul, Nilanjan Ghosh, Heather J. Symons, Javier Bolaños‐Meade, Douglas E. Gladstone, Lode J. Swinnen, Leo Luznik, Ephraim J. Fuchs, Richard J. Jones, Richard F. Ambinder

    Publicat 2013
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  15. 15
    Rituximab Extended Schedule or Re-Treatment Trial for Low–Tumor Burden Follicular Lymphoma: Eastern Cooperative Oncology Group Protocol E4402

    Rituximab Extended Schedule or Re-Treatment Trial for Low–Tumor Burden Follicular Lymphoma: Eastern Cooperative Oncology Group Protocol E4402 per Brad S. Kahl, Fangxin Hong, Michael E. Williams, Randy D. Gascoyne, Lynne I. Wagner, John C. Krauss, Thomas M. Habermann, Lode J. Swinnen, Stephen J. Schuster, Christopher G. Peterson, Mark D. Sborov, Sabrina Martín, Matthias Weiss, W. Christopher Ehmann, Sandra J. Horning

    Publicat 2014
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  16. 16
    Rituximab extended schedule or retreatment trial for low tumour burden non‐follicular indolent B‐cell non‐Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402

    Rituximab extended schedule or retreatment trial for low tumour burden non‐follicular indolent B‐cell non‐Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402 per Michael E. Williams, Fangxin Hong, Randy D. Gascoyne, Lynne I. Wagner, John C. Krauss, Thomas M. Habermann, Lode J. Swinnen, Stephen J. Schuster, Christopher G. Peterson, Mark D. Sborov, Sabrina Martín, Matthias Weiss, W. Christopher Ehmann, Sandra J. Horning, Brad S. Kahl

    Publicat 2016
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  17. 17
    Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide

    Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide per Yvette L. Kasamon, Richard F. Ambinder, Ephraim J. Fuchs, Marianna Zahurak, Gary L. Rosner, Javier Bolaños‐Meade, Mark J. Levis, Douglas E. Gladstone, Carol Ann Huff, Lode J. Swinnen, William Matsui, Ivan Borrello, Robert A. Brodsky, Richard J. Jones, Leo Luznik

    Publicat 2017
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  18. 18
    Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101

    Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101 per Tracy T. Batchelor, Sharmila Giri, Amy S. Ruppert, Susan M. Geyer, Scott E. Smith, Nimish Mohile, Lode J. Swinnen, Jonathan W. Friedberg, Brad S. Kahl, Nancy L. Bartlett, Eric D. Hsi, Bruce D. Cheson, Nina D. Wagner‐Johnston, Lakshmi Nayak, John P. Leonard, James L. Rubenstein

    Publicat 2024
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  19. 19
    Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation

    Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation per Yvette L. Kasamon, Ephraim J. Fuchs, Marianna Zahurak, Gary L. Rosner, Heather J. Symons, Douglas E. Gladstone, Carol Ann Huff, Lode J. Swinnen, Robert A. Brodsky, William Matsui, Ivan Borrello, Satish Shanbhag, Kenneth R. Cooke, Richard F. Ambinder, Leo Luznik, Javier Bolaños‐Meade, Richard J. Jones

    Publicat 2018
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  20. 20
    Major Histocompatibility Mismatch and Donor Choice for Second Allogeneic Bone Marrow Transplantation

    Major Histocompatibility Mismatch and Donor Choice for Second Allogeneic Bone Marrow Transplantation per Philip Imus, Amanda L. Blackford, Maria Bettinotti, Brian Iglehart, August Dietrich, Noah Tucker, Heather J. Symons, Kenneth R. Cooke, Leo Luznik, Ephraim J. Fuchs, Robert A. Brodsky, William Matsui, Carol Ann Huff, Douglas E. Gladstone, Richard F. Ambinder, Ivan Borrello, Lode J. Swinnen, Richard J. Jones, Javier Bolaños‐Meade

    Publicat 2017
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:

Eines de cerca: